Virios therapeutics announces fourth quarter and full year 2023 financial results

Atlanta, feb. 29, 2024 (globe newswire) -- virios therapeutics, inc. (nasdaq: viri) (the “company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“fm”) and long-covid (“lc”), today announced financial results for the fourth quarter and full year ended december 31, 2023.

VIRI Ratings Summary

VIRI Quant Ranking